Fed. Circ. Trims Daiichi Costs Award In Levaquin Suit

Law360 (June 10, 2009, 12:00 AM EDT) -- A federal appeals court has nixed some of the costs awarded to Daiichi Pharmaceutical Co. Ltd. after it won a patent dispute over its antibiotic drug Levaquin against Mylan Laboratories Inc., citing the fact that Mylan shared discovery costs with another generics maker in a separate infringement suit.

The U.S. Court of Appeals for the Federal Circuit on Wednesday remanded the case to the U.S. District Court for the Northern District of West Virginia, finding that discovery costs awarded Daiichi should have been apportioned between that...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.